Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1267658 | 0.79 | ALOX15 (0.42) | ALOX15LMNASMN1; SMN2KCNH2MMP12 | |
| SCHEMBL1201912 | 0.73 | SLC22A6 (0.30) | — | |
| SCHEMBL5257823 | 0.69 | MEN1 (0.30) | — | |
| SCHEMBL27561061 | 0.66 | — | — | |
| SCHEMBL6630941 | 0.66 | TDP1 (0.37) | SMN1; SMN2 | |
| SCHEMBL6789228 | 0.64 | HSPD1 (0.32) | — | |
| SCHEMBL15194156 | 0.64 | TSHR (0.38) | TSHR | |
| SCHEMBL6153718 | 0.64 | LMNA (0.67) | ALOX15LMNASMN1; SMN2MMP12TSHR | |
| SCHEMBL10414980 | 0.63 | LMNA (0.60) | ALOX15LMNASMN1; SMN2MMP12TSHR | |
| SCHEMBL11422717 | 0.63 | ALDH1A1 (0.37) | ALOX15LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026383-B2 | Process for the preparation of intermediates useful in the synthesis of statin derivatives | BASF SE (DE) | 2011-09-27 | — | — | US | disclosed |
| US-20110046411-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES | CIBA SPECIALTY CHEMICALS CORPORATION | 2011-02-24 | — | — | US | disclosed |
| US-7504532-B2 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-17 | — | — | US | disclosed |
| US-20080125601-A1 | PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, INTERMEDIATES THEREOF AND METHODS FOR THEIR PREPARATION | BASF SE (DE) | 2008-05-29 | — | — | US | disclosed |
| US-7317123-B2 | Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | TEVA PHARMACEUTICAL INDUSTRIES, LTD (IL) | 2008-01-08 | — | — | US | disclosed |
| US-20040242916-A1 | Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | BASF SE (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046411-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES | HMGCR, SREBF1, LCAT | ALOX15 278/4885LMNA 1340/4885SMN1; SMN2 4494/4885 |
| US-20080125601-A1 | PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, INTERMEDIATES THEREOF AND METHODS FOR THEIR PREPARATION | HMGCR, DHCR7, CYP8B1 | ALOX15 208/4885LMNA 675/4885SMN1; SMN2 2174/4885 |
| US-20040242916-A1 | Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | HMGCR, DHCR7, CYP8B1 | ALOX15 234/4885LMNA 421/4885SMN1; SMN2 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.